GTHP — Guided Therapeutics Share Price
0.000.00%
Last trade - 00:00- $8.19m
- $9.80m
- $0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,169.51 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -29128.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.1 | 0.08 | 0.01 | 0.1 | 0.01 | n/a | n/a | -27.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Directors
- Michael James NEC (62)
- Gene Cartwright CEO (67)
- Mark Faupel COO (65)
- Richard Fowler SVP (63)
- Richard Blumberg DRC (65)
- John Imhoff IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 27th, 1992
- Public Since
- July 1st, 1997
- No. of Shareholders
- 155
- No. of Employees
- 4
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 77,967,594
- Address
- Suite 300, 4955 Avalon Ridge Pkwy, NORCROSS, 30071
- Web
- https://www.guidedinc.com/
- Phone
- +1 7702428723
- Auditors
- UHY LLP
Upcoming Events for GTHP
Q2 2025 Guided Therapeutics Inc Earnings Release
Similar to GTHP
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the Guided Therapeutics share price?
As of Today at 20:59 UTC, shares in Guided Therapeutics are trading at $0.11. This share price information is delayed by 15 minutes.
How has the Guided Therapeutics share price performed this year?
Shares in Guided Therapeutics last closed at $0.11 and the price had moved by -3.67% over the past 365 days. In terms of relative price strength the Guided Therapeutics share price has underperformed the S&P500 Index by -10.68% over the past year.
What are the analyst and broker recommendations for Guided Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Guided Therapeutics dividend yield?
Guided Therapeutics does not currently pay a dividend.
Does Guided Therapeutics pay a dividend?
Guided Therapeutics does not currently pay a dividend.
When does Guided Therapeutics next pay dividends?
Guided Therapeutics does not currently pay a dividend.
How do I buy Guided Therapeutics shares?
To buy shares in Guided Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Guided Therapeutics?
As of the previous close price of $0.11, shares in Guided Therapeutics had a market capitalisation of $8.19m.
Where are Guided Therapeutics shares listed?
Here are the trading details for Guided Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GTHP
What kind of share is Guided Therapeutics?
Based on an overall assessment of its quality, value and momentum Guided Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Guided Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Guided Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Guided Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -34.2%.
As of the last closing price of $0.11, shares in Guided Therapeutics were trading -18.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Guided Therapeutics PE Ratio?
The Guided Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Guided Therapeutics?
Guided Therapeutics' management team is headed by:
- Michael James - NEC
- Gene Cartwright - CEO
- Mark Faupel - COO
- Richard Fowler - SVP
- Richard Blumberg - DRC
- John Imhoff - IND